Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting
approximately 1% of the world's population. This disease is associated with considerable …

The last decade of research into the pharmacogenetics of antipsychotics has seen the
development of genetic tests to determine the patients' metabolic status and the first attempts …

Olanzapine, aripiprazole and risperidone are atypical antipsychotics or neuroleptics widely
used for schizophrenia treatment. They induce various adverse drug reactions depending …

Objective: To evaluate the efficacy and safety of an extended-release (ER) formulation of
paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to …

Cytochrome P450 (CYP) drug oxidases play a pivotal role in the elimination of antipsychotic
agents, and therefore influence the toxicity and efficacy of these drugs. Factors that affect …

Individual and population differences in polymorphic cytochrome P 450 enzyme function
have been known for decades. The biological significance of these differences has now …

9.4 Concluding Remarks In this chapter, the authors attempted to show how considerations
of pharmacokinetics and metabolism guide the process of developing drugs with improved …

What is known and objective The underlying pathophysiology of autism spectrum disorder
(ASD) has been linked to immune dysregulation, oxidative stress and excitation‐inhibition …

When the risk of agranulocytosis associated with clozapine, the prototype of the second-
generation neuroleptics, became apparent, its prescription was restricted to patients …

Objective: Little is known about the role of CYP2D6 polymorphism in risperidone-induced
prolactin release in children. Method: Twenty-five children (aged 5-15 years) with pervasive …